Aminoguanidine does not inhibit aldose reductase activity in galactose-fed rats

Journal of Diabetes and its Complications

Volumn 10, Issue 1, 1996, Pages 23-30

  Dvornik, Dushan ^a   Hohman, Thomas C ^a   Basso, Michael D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; GALACTITOL; GALACTOSE; GUANIDINE DERIVATIVE; METHYLGUANIDINE; MINALRESTAT; TOLRESTAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATTLE; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROCYTE; LENS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RETINA; SCIATIC NERVE;

EID: 0030021120     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/1056-8727(94)00054-9     Document Type: Article

References (67)

1. Schuler W: Zur Hemmung der Diaminoöxydase (Histaminase). Experientia 8:230-232, 1952.
2. Schayer RW, Smiley RL, Kennedy J: Diamine oxidase and cadaverine metabolism. J Biol Chem 206:461-464, 1954.
3. Lindell SE, Nilsson K, Ross BE, Westling H: The effect of enzyme inhibitors on histamine catabolism in man. Br J Pharmacol 15:351-355, 1960.
4. Baylin SB, Beaven MA, Engelman K, Sjoerdsma A: Elevated histaminase activity in medullary carcinoma of the thyroid gland. N Engl J Med 283:1239-1244, 1970.
5. Baylin SB, Beaven MA, Buja LM, Keiser HR: Histaminase activity: A biochemical marker for medullary carcinoma of the thyroid. Am J Med 53:723-733, 1972.
6. Missala K, Sourkes TL: Putrescine catabolism in rats given heparin or aminoguanidine. Eur J Pharmacol 64: 307-311, 1980.
7. Kusche J, Menningen R, Leisten L, Amoei B: Elevation of the large bowel histamine concentration by aminoguanidine induced diamine oxidase inhibition. Agents Actions 20:274-276, 1987.
8. Hirsch J, Baynes JW, Blackledge JA, Feather MS: The reaction of 3-deoxy-D-glycero-pentos-2-ulose ("3-deoxyglucosone") with aminoguanidine. Carbohyd Res 220:5-7, 1991.
9. Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41:26-19, 1992.
10. Requena JR, Vidal P, Cabezas-Cerrato J: Aminoguanidine inhibits protein browning without extensive Amadori carbonyl blocking. Diabetes Res Clin Pract 19:23-30, 1993.
11. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW: Glycation, glucoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43:676-683, 1994.
12. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, McDaniel ML: Aminoguanidine, a novel inhibitor of nitric oxide formation prevents diabetic vascular dysfunction. Diabetes 41:552-556, 1992.
13. Corbett JA, McDaniel ML: Does nitric oxide mediate autoimmune destruction of β-cells? Possible therapeutic interventions in IDDM. Diabetes 41:897-903, 1992.
14. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR: Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42:221-232, 1993.
15. Misko TP, Moore WM, Kasten TP, Nichols GA, Corbett JA, Tilton RG, McDaniel ML, Williamson JR, Carrie MG: Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 233:119-125, 1993.
16. Griffiths MJD, Messent M, MacAllister RJ, Evans TW: Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 110:963-968, 1993.
17. G-nitro-L-arginine, and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun 199: 147-154, 1994.
18. Ou P, Wolff SP: Aminoguanidine: A drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem Pharmacol 46:1139-1144, 1993.
19. Kumari K, Umar S, Bansal V, Sahib MK: Monoaminoguanidine inhibits aldose reductase. Biochem Pharmacol 41:1527-1528, 1991.
20. Kumari K, Murthy PSR, Sahib MK: Monoaminoguanidine prevents sorbitol accumulation, nonenzymatic protein glycosylation and development of kidney lesions in diabetic rats. Experientia 47:252-254, 1991.
21. Kumari K, Umar S, Bansal V, Sahib MK: Inhibition of diabetes-associated complications by nucleophilic compounds. Diabetes 40:1079-1084, 1991.
22. Hayman S, Kinoshita JH: Isolation and properties of lens aldose reductase. J Biol Chem 240:877-882, 1965.
23. Simard-Duquesne N, Greselin E, Dubuc J, Dvornik D: The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats. Metabolism 34: 885-892, 1985.
24. Dvornik D: Animal models of diabetic complications and their relation to aldose reductase inhibition, in Porte D (ed), Aldose Reductase Inhibition. An Approach to the Prevention of Diabetic Complications. New York, BIC/ McGraw Hill, 1987, pp. 153-219.
25. Dvornik D: Aldose reductase inhibitors, in Porte D (3d), Aldose Reductase Inhibition. An Approach to the Prevention of Diabetic Complications. New York, BIC/McGraw Hill, 1987, pp. 221-323.
26. Lightman S, Bondy C, Lightman S, Kador P: Aldose reductase messenger RNA in the lens epithelium in vivo: effects of diabetes and galactosemia. Clin Sci 79: 599-603, 1990.
27. Bondy C, Cowley AD, Lightman SL, Kador PF: Feedback inhibitor of aldose reductase gene expression in rat renal medulla. J Clin Invest 86:1103-1108, 1990.
28. Sato S: Rat kidney aldose reductase and aldehyde reductase and polyol production in the kidney. Am J Physiol 263:F799-F805, 1992.
29. Cameron NE, Cotter MA, Robertson S, Cox D: Muscle and nerve dysfunction in rats with experimental galactosemia. Exp Physiol 77:89-108, 1992.
30. Cotter MA, Cameron NE, Robertson S: Polyol pathway-mediated changes in cardiac muscle contractile properties: studies in streptozotocin and galactose-fed rats. Exp Physiol 77:828-838, 1992.
31. Cameron NE, Cotter MA: Contraction and relaxation of aortas from galactosaemic rats and the effects of aldose reductase inhibition. Eur J Pharmacol 243:47-53, 1993.
32. Dvornik D, Millen J, Hicks DR, Kraml M: Tolrestat pharmacokinetics in rat peripheral nerves. J Diabet Complications 8:18-26, 1994.
33. Sato S, Kador PF: Human kidney aldose and aldehyde reductases. J Diabet Complications 7:179-187, 1993.
34. Nakayama T, Kador PF: Polyol production in human red blood cell, in Sakamoto N, Kinoshita JH, Kador PF, Hotta N (eds), Current Concepts of Aldose Reductase and its Inhibition. Amsterdam, Excerpta Medica, 1990, pp. 59-63.
35. Sestanj K, Bellini F, Fung S, Abraham N, Treasurywala A, Humber L, Simard-Duquesne N, Dvornik D: N-[[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N-methylglycine (tolrestat), a potent, orally active aldose reductase inhibitor. J Med Chem 27:255-256, 1984.
36. Malamas MS, Hohman TC: Characterization of a structurally novel, highly potent, orally active aldose reductase inhibitor. Diabetologia 35(suppl 1):A49, 1992.
37. Malamas MS, Hohman TC, Millen J: Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones:2-(4-bromo-2-fluorophenyl)-methyl]-6-fluorospiro- [isoquinoline-4(1H),3′ pyrrolidine]-1,2′3,5′ (2H)-tetrone and congeners. 1. J Med Chem 37:2043-2058, 1994.
38. Sima AAF, Greene DA, Brown MB, Hohman TC, Hicks D, Graepel GJ, Bochenek WJ, Beg M, Gonen B, The Tolrestat Study Group. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. J Diabet Complications 7:157-169, 1993.
39. Guerrant GO, Moss CW: Determination of monosaccharides as aldononitrile, O-methyloxime, alditol, and cyclitol acetate derivatives by gas chromatography. Anal Chem 56:633-638, 1984.
40. Dickerson FE Jr, Lou MF: Macro-quantitation of lens myo-inositol by anion exchange chromatography. Current Eye Res 9:201-205, 1990.
41. Simard-Duquesne N, Greselin E, Gonzalez R, Dvornik D: Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, tolrestat. Proc Soc Exp Biol Med 178:599-605, 1985.
42. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555-11558, 1991.
43. Odetti PR, Borgoglio A, DePascale A, Rolandi R, Adezati L: Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes 39:796-801, 1990.
44. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA: Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 88: 6107-6111, 1991.
45. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40:1328-1334, 1991.
46. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K: Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 41:47-52, 1992.
47. Oxlund H, Andreassen TT: Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes. Diabetologia 35:19-25, 1991.
48. Cameron NE, Cotter MA, Dines K, Love A: Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35:946-950, 1992.
49. 14 aminoguanidine by rat tissues. Fed Proc 20:174, 1961.
50. Beaven MA, Gordan JVV, Jacobsen S, Severs WB: A specific and sensitive assay for aminoguanidine: Its application to a study of the deposition of aminoguanidine in animal tissues. J Pharmacol Exp Ther 165:14-22, 1969.
51. Lewis BS, Harding JJ: The effects of aminoguanidine on the glycation (non-enzymic glycosylation) of lens proteins. Exp Eye Res 50:463-467, 1990.
52. Dvornik D, Millen J, Hicks D, Cayen M, Sredy J: The pharmacokinetics of aldose reductase inhibitors, in Sakamoto H, Kinoshita JH, Kador PF, Hotta N (eds), Polyol Pathway and Its Role in Diabetic Complications. Amsterdam, Elsevier, 1988, pp. 61-71.
53. Williamson JR, Chang K, Ido Y, Ostrow E, Allison W, Harlow J, Tilton RG: L'aminoguanidine empêche l'augmentation de la perméabilité vasculaire induite par le diabète (streptozotocine) dans le nerf sciatique du rat. Diabete Metab 16:369-370, 1990.
54. Ellis EN, Good BH: Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 40:1016-1019, 1991.
55. Itakura M, Yoshikawa H, Bannai C, Kato M, Kunika K, Kawakami Y, Yamaoka T, Yamashita K: Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats. Life Sci 49:889-897, 1991.
56. Bannai C, Yamazaki M, Matsushima Y, Kunika K, Itakura M, Okuda Y, Yamashita K: Amelioration of dermal lesions in streptozotocin-induced diabetic rats by aminoguanidine. Diabetes Res 20:87-95, 1992.
57. Sugimoto K, Nishida N, Wada RI: Effects of aminoguanidine on endoneurial vascular abnormalities in experimental diabetic neuropathy. Diabetes 43(suppl 1):16A, 1994.
58. Edelstein C, Brownlee M: Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35:96-97, 1991.
59. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K: Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37:32-35, 1994.
60. Huijberts MSP, Wolfenbuttel BHR, Struijker Boudier HAJ, Crijns FRL, Nieuwenhuijzen Kruseman AC, Poitevin P, Levy BI: Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 92:1407-1411, 1993.
61. Huijberts MSP, Wolfenbuttel BHR, Crijns FRL, Nieuwenhuijzen Kruseman AC, Bemelmans MHA, Struijker Boudier HAJ: Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats. Diabetologia 37:10-14, 1994.
62. Oturai P, Hasselager E, Myrup B, Kofoed-Enevoldsen A, Thomsen M, Deckert T: Increased rate of kidney tumors in aminoguanidine-treated STZ-diabetic rats. Diabetes 43(suppl 1):204A, 1994.
63. Gonzalez AM, Sochor M, McLean P: The effect of an aldose reductase inhibitor (sorbinil) on the level of metabolites in lenses of diabetic rats. Diabetes 32:482-485, 1983.
64. Kinoshita JH, Merola LO, Dikmak E: Osmotic changes in experimental galactose cataracts. Exp Eye Res 1:405-410, 1962.
65. Sasaki K, Kuriyama H, Yeh LI, Fukuda M: Studies on diabetic cataract in rats induced by streptozotocin. Ophthalmic Res 15:185-190, 1983.
66. Kuriyama H, Sasaki K, Fukuda M: Studies on diabetic cataract in rats induced by streptozotocin. II. Biochemical examination of rat lenses in relation to cataract stages. Ophthalmic Res 15:191-197, 1983.
67. Kinoshita JH: Cataracts in galactosemia. Invest Ophthalmol 4:786-799, 1965.